Related references
Note: Only part of the references are listed.Using the Galactose-α-1,3-Galactose Enzyme-Linked Immunosorbent Assay to Predict Anaphylaxis in Response to Cetuximab
Jared Weiss et al.
CANCER (2016)
Risk factors for and pre-medications to prevent cetuximab-induced infusion reactions in patients with squamous cell carcinoma of the head and neck
Waseem Touma et al.
ORAL ONCOLOGY (2014)
Incidence of cetuximab-related infusion reactions in oncology patients treated at the University of North Carolina Cancer Hospital
Karen Keating et al.
JOURNAL OF ONCOLOGY PHARMACY PRACTICE (2014)
Platinum-based Chemotherapy Plus Cetuximab for the First-line Treatment of Japanese Patients with Recurrent and/or Metastatic Squamous Cell Carcinoma of the Head and Neck: Results of a Phase II Trial
Takayuki Yoshino et al.
JAPANESE JOURNAL OF CLINICAL ONCOLOGY (2013)
Phase II Study of Cetuximab Plus Concomitant Boost Radiotherapy in Japanese Patients with Locally Advanced Squamous Cell Carcinoma of the Head and Neck
Susumu Okano et al.
JAPANESE JOURNAL OF CLINICAL ONCOLOGY (2013)
Reduced Incidence of Infusion-Related Reactions in Metastatic Colorectal Cancer During Treatment With Cetuximab Plus Irinotecan With Combined Corticosteroid and Antihistamine Premedication
Salvatore Siena et al.
CANCER (2010)
Incidence and predictors of cetuximab hypersensitivity reactions in a North Carolina academic medical center
Nicole L Hansen et al.
JOURNAL OF ONCOLOGY PHARMACY PRACTICE (2010)
Fluorouracil, Leucovorin, and Oxaliplatin With and Without Cetuximab in the First-Line Treatment of Metastatic Colorectal Cancer
Carsten Bokemeyer et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Cetuximab Plus Irinotecan in Heavily Pretreated Metastatic Colorectal Cancer Progressing on Irinotecan: MABEL Study
Hansjochen Wilke et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Cetuximab-induced anaphylaxis and IgE specific for galactose-α-1,3-galactose
Christine H. Chung et al.
NEW ENGLAND JOURNAL OF MEDICINE (2008)
Platinum-based chemotherapy plus cetuximab in head and neck cancer
Jan B. Vermorken et al.
NEW ENGLAND JOURNAL OF MEDICINE (2008)
High incidence of cetuximab-related infusion reactions in Tennessee and North Carolina and the association with atopic history
Bert H. O'Neil et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Phase II study of combination cetuximab and weekly paclitaxel in patients with metastatic/recurrent squamous cell carcinoma of head and neck (SCCHN): Spanish Head and Neck Cancer Group (TTCC)
R. Hitt et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Open-label, uncontrolled, multicenter phase II study to evaluate the efficacy and toxicity of cetuximab as a single agent in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck who failed to respond to platinum-based therapy
Jan B. Vermorken et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Management and preparedness for infusion and hypersensitivity reactions
Heinz-Josef Lenz
ONCOLOGIST (2007)
Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck
JA Bonner et al.
NEW ENGLAND JOURNAL OF MEDICINE (2006)
Phase II trial of cetuximab in patients with refractory colorectal cancer that expresses the epidermal growth factor receptor
LB Saltz et al.
JOURNAL OF CLINICAL ONCOLOGY (2004)
Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer
D Cunningham et al.
NEW ENGLAND JOURNAL OF MEDICINE (2004)
Share Paper
